Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment
Explore this paper's citation graph
Summary
The current evidence for optimal treatment of EBC is summarized in this review to help evaluate the impact of current standard treatments in long-term outcome and safety.
- Type
- article
- Published
- 2013-09-01
- Cited by
- 8
- References
- 170
- Access
- Open access
- OpenAlex
- https://openalex.org/W26217109
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:17176471
Keywords
Humanities, Art, Philosophy
References
- Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.
- A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen
- Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
- Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management.
- Indications for neoadjuvant chemotherapy for breast cancer.
- Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
- A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
- Gene-expression signatures in breast cancer.
- aTTom (adjuvant Tamoxifen--To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results
- Functional evaluation of plasmin formation in primary breast cancer.
- HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
- Trastuzumab containing regimens for early breast cancer.
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
- Proliferation marker Ki-67 in early breast cancer.
- 2012 ESMO congress
- Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
- Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
- Abstract S1-1: Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial.
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Cited by
- Breast Cancer Under Age 40: a Different Approach
- An approach to the management of locally advanced breast cancer: part 1.
- Fatores prognósticos e preditivos da resposta clínica e patológica em mulheres com carcinoma de mama submetidas a quimioterapia neoadjuvante : Prognostic and predictive factors of the clinical and pathological response in women with breast carcinoma submitted to neoadjuvant chemotherapy
- Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma
- Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
- Comprehensive characterization of RNA cargo of extracellular vesicles in breast cancer patients undergoing neoadjuvant chemotherapy
- Immunohistochemical Study of P 53 and Ki 67 Expression in Surface Epithelial Tumor of the Ovary
- Cardiotoxicity: Cardiac Ischemia
Related papers
No related papers recorded.